Sawyer, Sara J., Suzanne M. Norvell, Suzanne M. Ponik, and Fredrick M. Pavalko. Regulation of PGE 2 and PGI2 release from human umbilical vein endothelial cells by actin cytoskeleton. Am J Physiol Cell Physiol 281: C1038-C1045, 2001.-Disruption of microfilaments in human umbilical vein endothelial cells (HUVEC) with cytochalasin D (cytD) or latrunculin A (latA) resulted in a 3.3-to 5.7-fold increase in total synthesis of prostaglandin E 2 (PGE2) and a 3.4-to 6.5-fold increase in prostacyclin (PGI2) compared with control cells. Disruption of the microtubule network with nocodazole or colchicine increased synthesis of PGE2 1.7-to 1.9-fold and PGI2 1.9-to 2.0-fold compared with control cells. Interestingly, however, increased release of PGE 2 and PGI2 from HUVEC into the media occurred only when microfilaments were disrupted. CytD treatment resulted in 6.7-fold more PGE2 and 3.8-fold more PGI2 released from HUVEC compared with control cells; latA treatment resulted in 17.7-fold more PGE 2 and 11.2-fold more PGI2 released compared with control cells. Both increased synthesis and release of prostaglandins in response to all drug treatments were completely inhibited by NS-398, a specific inhibitor of cyclooxygenase-2 (COX-2). Disruption of either microfilaments using cytD or latA or of microtubules using nocodazole or colchicine resulted in a significant increase in COX-2 protein levels, suggesting that the increased synthesis of prostaglandins in response to drug treatments may result from increased activity of COX-2. These results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest that the cytoskeleton plays an important role in maintenance of endothelial barrier function by regulating prostaglandin synthesis and release from HUVEC.
cyclooxygenase; microfilaments; microtubules; vasoprotection; prostaglandin E 2; prostacyclin THE ACTIN CYTOSKELETON PLAYS a complex role in the maintenance of endothelial barrier function. Tight cellcell adhesion and strong attachments to the extracellular matrix through focal adhesions correlates with low endothelial permeability (4, 14, 19, 35) . Many agonists, like thrombin, increase axial contractility by inducing actin-myosin stress fiber formation that promotes formation of intracellular gaps and compromises barrier function (14, 15) . Additionally, disassembly of actin filaments using pharmacological agents also decreases endothelial integrity and barrier function (3, 27, 33, 37) .
Several studies have demonstrated that cytoskeletal reorganization and loss of barrier function correlate with increased release of prostaglandin E 2 (PGE 2 ) and prostacyclin (PGI 2 ) (11, 25, 28, 39) . Important steps in the regulation of prostaglandin synthesis include cleavage of arachidonic acid (AA) from membrane phospholipids by phospholipase A 2 (PLA 2 ) and the conversion of AA to prostaglandin H 2 by cyclooxygenases (COX) (20, 21) . Activity of the two isoenzymes of COX, cyclooxygenase-1 (COX-1), which is constitutively expressed, and cyclooxygenase-2 (COX-2), which is induced in many types of cells by a variety of agonists, (9, 10) is controlled primarily at the level of transcription and translation. However, some posttranslational modification of the enzyme also occurs that may regulate activity (32) . The mechanisms that regulate prostaglandin production by cells, however, remain largely unknown. Also unclear is whether prostaglandin release from cells occurs simply as a result of increased prostaglandin synthesis or if prostaglandin release is an actively regulated process that can be controlled independently of increased synthesis. PGE 2 and PGI 2 are vasodilatory prostaglandins released by endothelial cells (34) . Release of PGI 2 from endothelial cells is stimulated by many factors, including hypoxia, lipopolysaccharide (LPS), endotoxin, and fluid shear stress (1, 18, 23, 30) . Each of these stimuli also increases production of COX-2 mRNA and protein by endothelial cells (1, 8, 22, 23, 30) . Under conditions in which endothelial barrier function is compromised, PGE 2 and PGI 2 have been shown to play a vasoprotective role. That is, these prostaglandins can protect the vasculature from damage associated with conditions in which barrier permeability is increased (6, 24) . Welles et al. (43) suggested that PGI 2 could actually decrease endothelial permeability in the microvasculature by promoting the reorganization of microfilaments. Thus PGE 2 and PGI 2 release may be coordinately regulated, at least in part, by changes in the normal organization of cytoskeletal filaments as part of a vasoprotective response that helps maintain the integrity of endothelial barrier function in the vasculature.
In this study, we have examined directly the effect of microfilament and microtubule disruption on PGE 2 and PGI 2 synthesis and release in human umbilical vein endothelial cells (HUVEC). Disruption of either microtubules (using nocodazole or colchicine) or microfilaments [using cytochalasin D (cytD) or latrunculin A (latA)] resulted in significant increases in prostaglandin synthesis, whereas only disruption of the actin cytoskeleton increased release of PGE 2 and PGI 2 from HUVEC. These studies demonstrate that increased synthesis of prostaglandins in HUVEC does not always result in increased prostaglandin release and suggest that actin filament-regulated PGE 2 and PGI 2 release may represent a vasoprotective response during conditions in which endothelial barrier function is compromised.
MATERIALS AND METHODS
Cell culture. HUVEC were obtained from Clonetics (East Rutherford, NJ) and grown in endothelial growth media (Clonetics) containing 2% fetal bovine serum, 12 g/ml bovine brain extract, 1 g/ml human epidermal growth factor, and 1 g/ml hydrocortisone, gentamicin, and amphotericin B. Cells were maintained in 5% CO 2 at 37°C, and experiments were performed using cells between passages 2 and 4.
Experimental protocol. Cells were grown on glass slides coated with 10 g/ml of human plasma fibronectin (GIBCO Life Technologies, Carlsbad, CA) until confluent. Cells were pretreated for 1 h with either vehicle control [0.1% dimethyl sulfoxide (DMSO)], 0.2 M cytD, 50 nM latA, 10 M nocodazole, or 10 M colchicine or overnight with 10 M NS-398. DMSO, cytD, nocodazole, and colchicine were purchased from Sigma Chemical (St. Louis, MO); latA and NS-398 were purchased from Calbiochem (La Jolla, CA). The cells were incubated for 6 h in DMEM containing 0.5% FCS and the appropriate pharmacological agent. At the end of the 6-h treatment, the cells were collected for either immunocytochemistry, Western blot analysis, or prostaglandin measurement.
Immunocytochemistry. Cells were rinsed twice in phosphate-buffered saline (PBS) and preserved in 4% paraformaldehyde for 15 min. Microtubules were visualized by staining with an anti-␣-tubulin antibody (Sigma) followed by an appropriate rhodamine-labeled secondary antibody (Jackson Immunoresearch, West Grove, PA). Microfilaments were stained with FITC-phalloidin (Molecular Probes, Eugene, OR). Images were recorded using an RT Color Spotdigital camera (Diagnostic Instruments, Sterling Heights, MI) using an Optiphot-2 Nikon epifluorescent microscope.
Western blot analysis. Cells were harvested by direct lysis in SDS sample buffer and homogenized by shearing through a 25-gauge needle. Protein concentrations were determined using the amido black method (38) . Equal protein (20 g) was loaded onto a 7.5% SDS-PAGE gel for separation and transferred to nitrocellulose for immunoblot analysis. COX-1 and COX-2 antibodies were purchased from Cayman; the vinculin antibody, VIN-11-5, was obtained from Sigma Chemical. The appropriate horseradish peroxidase-labeled secondary antibodies were obtained from Jackson Immunoresearch, and the antibody signal was detected by enhanced chemiluminescence. Each experiment was carried out in at least triplicate, and scanning densitometry of bands was performed with the Bio-Rad (Hercules, CA) Molecular Analyst program.
Prostaglandin measurement. Prostaglandin release from cells was measured by incubating the cells in 1 ml of DMEM containing the appropriate drugs for 30 min after the 6-h treatment. The media were collected and centrifuged at 12,000 g for 2 min to pellet any particulates. The supernatant was transferred to a fresh tube and retained for prostaglandin analysis. To determine the amount of prostaglandins retained in the cells after drug treatment, cells were rinsed twice with PBS, harvested in a hypotonic buffer (50 mM Tris, 0.1 mM EGTA, pH 7.4), and incubated for 5 min on ice before removal of the insoluble material by centrifugation at 12,000 g for 2 min. The supernatant was transferred to a fresh tube and retained for prostaglandin analysis. PGE2 and PGI2 were measured with the appropriate enzyme immunoassay kit from Amersham Pharmacia Biotech (Piscataway, NJ) according to the manufacturer's instructions. Results were normalized to total cellular protein as determined by the bicinchoninic acid reagent (BCA; Pierce Chemical, Rockford, IL) in the lysates.
PLA2 activity assays. PLA2 was measured using an activity kit purchased from Cayman Chemical (Ann Arbor, MI) according to the manufacturer's instructions.
Cell viability assay and apoptosis detection. Cell viability was determined by trypan blue exclusion. After treatment with the appropriate pharmacological agent, cells were harvested by trypsinization and incubated in 0.04% trypan blue (Sigma Chemical) for 4 min. Cells were counted with a hemacytometer, and the number of cells retaining the dye (nonviable) and the number of unstained cells was noted. To determine whether drug treatments induced apoptosis in HUVEC, DNA strand breaks were detected using a TdT-mediated dUTP nick end labeling (TUNEL) assay (Boehringer Mannheim, Indianapolis, IN). Cells were treated with the appropriate pharmacological agent for 6 h and then preserved in 4% paraformaldehyde. Cells were stained by TUNEL reaction according to the manufacturer's instructions. As a positive control, HUVEC were treated with 10 ng/ml of human tumor necrosis factor (TNF)-␣ (Sigma Chemical) for 24 h and were stained with the TUNEL antibody. At least 50 cells were counted for each treatment, and the percentage of cells that were apoptotic was determined.
Immunoprecipitation. After treatment, cells were harvested in immunoprecipitate buffer (10 mM Tris, pH 7.4, 145 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM vanadate, and 1 mM NaFl with phenylmethylsulfonyl fluoride, leupeptin, pepstatin, and aprotinin added as needed) and incubated on ice for 5 min before removing the insoluble material by centrifugation (5 min, 14,000 rpm). Protein concentration was determined by the BCA assay, and equal amounts of protein from each sample were incubated with 5 g of COX-2 antibody for 1 h at 4°C. The lysates were then incubated with 100 l of 10% rabbit anti-mouse protein A-Sepharose beads for 1 h. The beads were washed five times with immunoprecipitation buffer before extraction in SDS sample buffer and Western blot analysis.
Statistical analysis. Statistical analysis of the scanning densitometry of COX-1 and COX-2 and the PGE 2 and PGI2 measurements was made using the statistical package Statview.
RESULTS

Effects of cytoskeletal inhibitors on HUVEC.
HUVEC were treated for 6 h with either cytD (0.2 M) or latA (0.05 M) to disrupt microfilaments or with nocodazole (10 M) or colchicine (10 M) to disrupt microtubules. These drug concentrations were chosen based on the ability to effectively disrupt the appropriate cytoskeletal network (Fig. 1) without decreasing cell viability (assessed by trypan blue exclusion) or inducing apoptosis (based on TUNEL staining). Cell viability in all conditions was never less than that of the 0.1% DMSO control treatment (88% viable after trypsinization). In cells treated with TNF-␣, 18.5% of the cells stained positive by the TUNEL assay, whereas only 1.3% of the vehicle-treated cells stained positive. The percentage of apoptotic cells measured by positive TUNEL staining was 2.2% in both the cytD-and latA-treated cells and 1.2 and 1.5% in the nocodazole-and colchicinetreated cells, respectively.
Drug-treated cells were slightly more rounded than untreated cells but remained firmly attached to the substrate. When visualized by immunofluorescence microscopy, untreated cells had normal microfilament and microtubule networks, whereas the microfilaments of cells treated with cytD or latA were completely disrupted (Fig. 1) . In cells treated with cytD or latA, the microtubule network consistently appeared thinner and less well organized than that of untreated control cells, although intact microtubules were always present in these cells. Nocodazole or colchicine treatment eliminated microtubules but did not disrupt the microfilament cytoskeleton. Instead, as has been reported previously (7), microtubule disruption appeared to cause an increase in the number and thickness of actin stress fibers. NS-398 had no affect on either cell shape or the organization of the microtubule or microfilament networks (data not shown).
Effects of cytoskeletal disruption on prostaglandin synthesis and release. To directly examine the effect of cytoskeletal disruption on prostaglandin synthesis in HUVEC, cells were treated with cytD, latA, nocodazole, colchicine, or vehicle (0.1% DMSO) alone for 6 h and then incubated for 30 min in 1 ml of medium. PGI 2 and PGE 2 in the media and in cell lysates were measured by enzyme immunoassay. All four drugs significantly increased total PGE 2 and PGI 2 synthesis, defined as the amount of each prostaglandin released into the media plus the amount retained in cell lysates (Fig.  2) . PGE 2 and PGI 2 synthesis in HUVEC treated with cytD was 3.3-and 3.4-fold higher compared with control cells (P Ͻ 0.002; Table 1 ); HUVEC treated with latA, PGE 2 , and PGI 2 were 5.7-and 6.6-fold higher, respectively, compared with control cells (P Ͻ 0.003; Table 1 ). Nocodazole-treated HUVEC produced 1.7-fold more PGE 2 and 2.0-fold more PGI 2 than control cells (P Ͻ 0.02 PGE 2 , P Ͻ 0.0004 PGI 2 ; Table 1 ); colchicine-treated HUVEC produced 1.9-fold more PGE 2 and 1.9-fold more PGI 2 than control cells (P Ͻ 0.004; Table 1 ). The increased levels of PGI 2 and PGE 2 in HUVEC treated with any of these drugs were completely inhibited by NS-398, a specific inhibitor of the enzyme COX-2. NS-398 also significantly inhibited synthesis of PGE 2 from controls cells (P Ͻ 0.01) and inhibited basal levels of PGI 2 (P Ͻ 0.08), suggesting that in the absence of cytoskeletal disruption, basal PGE 2 and PGI 2 synthesis in HUVEC is dependent on COX-2 activity.
We next compared the effect of cytoskeletal disruption specifically on prostaglandin release from HUVEC. A dramatic increase in PGE 2 and PGI 2 release into the media from cells treated with cytD or latA was observed compared with cells treated either with nocodazole, colchicine, or DMSO alone (Fig. 3) . Actin disruption resulting from cytD or latA treatment caused a striking 6.7-fold and 17.7-fold increase, respectively, in release of PGE 2 and a 3.8-fold and 11.2-fold increase in release of PGI 2 (Table 1) from HUVEC into the media compared with vehicletreated control cells (P Ͻ 0.01). The increased release of both PGE 2 and PGI 2 induced by cytD or latA treatment was completely blocked by NS-398 (P Ͻ 0.04). Additionally, cytD and latA increased the percentage of the total prostaglandins released from HUVEC (Fig. 4) . Compared with vehicle-treated controls, cytD treatment increased release of PGE 2 from 21% to 40% of the total PGE 2 , whereas the percentage of total PGI 2 that was released increased from 29% to 39%. The increased release of PGE 2 or PGI 2 following latA treatment was 51% and 56%, respectively. In contrast to the effects of cytD or latA on prostaglandin release from HUVEC, the amount of PGE 2 and PGI 2 released into the media by cells treated with nocodazole or colchicine was not significantly different from vehicle-treated control cells ( Fig. 4 ; Table 1 ). Compared with vehicle-treated controls, nocodazole and colchicine also did not alter the percentage of total prostaglandins that was released into the media. Control, nocodazole-, and colchicinetreated cells released 21, 9, and 17% of the total PGE 2 produced, respectively. Control, nocodazole-, and colchicine-treated cells released 29, 24, and 23% of the total PGI 2 produced, respectively (Fig. 4) . These results suggest that the actin cytoskeleton, but not microtubules, plays an important role in regulating the release of PGE 2 and PGI 2 from HUVEC. Fig. 2 . A and B: total prostaglandin E2 (PGE2) and prostacyclin (PGI2) production (amount released from ϩ amount retained by the cells) in HUVEC in response to various pharmacological agents. Cells treated with cytochalasin D, latrunculin A, nocodazole, or colchicine produced significantly more PGE2 and PGI2 than did control cells (P Ͻ 0.05). The drug-induced increase in prostaglandin production was completely inhibited by the cyclooxygenase-2 (COX-2) inhibitor NS-398 (P Ͻ 0.04). Effects of cytoskeletal disruption on PLA 2 activity and COX-2 tyrosine phosphorylation. To investigate the potential role of cytoskeleton-sensitive changes in PLA 2 activity in increased prostaglandin production, PLA 2 activity assays were performed on cell extracts after disruption of either microfilaments or microtubules. However, all drug treatments significantly decreased PLA 2 activity compared with control activity (P Ͻ 0.01; Fig. 5 ). Thus cytoskeletal disruption does not increase prostaglandin production through an effect on PLA 2 .
To investigate whether cytoskeletal disruption altered the activity of COX-2 through tyrosine phosphorylation, we determined the level of COX-2 tyrosine phosphorylation in HUVEC after a 6-h treatment with either cytD or nocodazole. No change in tyrosine phosphorylation levels was found in COX-2 immunoprecipitates (Fig. 6) , suggesting that if COX-2 enzymatic activity is altered by cytoskeletal disruption, it is not through tyrosine phosphorylation in HUVEC.
Effect of cytoskeletal disruption on COX-2 protein levels. To determine whether the increased synthesis of PGE 2 and PGI 2 in cytD-treated cells might result from increased expression of COX-2, the inducible isoform of COX, immunoblot analysis of protein extracts, was performed (Fig. 7) . Densitometry of a minimum of four separate experiments (summarized in Table 2 ) indicated a statistically significant increase in COX-2 protein levels in cells treated with cytD (2.0-fold), latA (2.4-fold), nocodazole (2.6-fold), or colchicine (2.8-fold), compared with vehicle-only controls. In contrast, expression of COX-1, the constitutive form of the enzyme, was not affected in cells treated with any of these drugs ( Fig. 7; Table 2 ). Thus the increased synthesis of PGE 2 and PGI 2 induced by disruption of either microfilaments or microtubules may be explained, at least in part, by increased expression of COX-2.
DISCUSSION
Our results support a role for the cytoskeleton in the synthesis and release of prostaglandins from HUVEC. Specifically, disruption of either microfilaments or microtubules resulted in increased synthesis of PGE 2 and PGI 2 compared with control cells. However, disruption of microfilaments, but not disruption of microtubules, induced a large increase in release of PGE 2 and PGI 2 into the media compared with control cells. When calculated as a percentage of total prostaglandin synthesis, PGE 2 release increased from 21% to 38-51%, and PGI 2 release increased from 28% to 39-56% after disruption of the actin cytoskeleton. However, microtubule disruption did not change the percentage of total prostaglandins released compared with control cells. Thus the amount of prostaglandins released from cells is not always proportional to total increases in prostaglandin synthesis. Instead, prostaglandin release may be actively regulated by the actin cytoskeleton. It is not clear why treatment of cells with latA results in significantly higher PGE 2 and PGI 2 production and release compared with cells treated with cytD. The explanation for this difference might lie in the fact that although both drugs lead to complete disassembly of actin stress fibers, the mechanisms of action of these two drugs are very different. While latA sequesters actin monomers and prevents their incorporation into filaments, cytD severs actin filaments and caps their barbed ends. Others (13, 42) have reported that cytD treatment results in much higher levels of insoluble F-actin remaining in cells compared with cells treated with latA. The increased synthesis of both PGE 2 and PGI 2 by cells with a disrupted actin or microtubule cytoskeleton was inhibited by NS-398 and was thus COX-2 dependent. Microfilament or microtubule disruption did not increase PLA 2 activity in cell extracts using an in vitro PLA 2 activity. However, COX-2 protein levels were increased significantly, suggesting that both filament systems play a role in the regulation of COX-2 protein expression and activity in HUVEC. On the basis of the data presented in this study, we conclude that COX-2 protein levels in cells and synthesis of prostaglandins is regulated by both microfilaments and microtubules, while release of prostaglandins is modulated, at least in part, by the actin cytoskeleton.
Others (12) have shown that endothelial cells with altered cytoskeletal organization increased release of PGI 2 ; however, these authors altered the actin cytoskeleton by plating the cells on substrates with differing adhesive capacities. Cells that were poorly adhered had a reduced actin network and released more PGI 2 . It is possible, however, that in those experiments, altering the adhesive extracellular matrix alone may also influence prostaglandin release. In our experiments, microfilaments and microtubules were directly disrupted using pharmacological agents at concentrations that did not compromise cell viability or induce apoptosis and had minimal affect on the morphology of the cell (Fig. 1) . Thus our experiments utilize multiple cytoskeletal poisons that function through different mechanisms to demonstrate a direct relationship between cytoskeletal organization and synthesis and release of PGE 2 and PGI 2 .
In other cell types, including human mammary epithelial cells (41) and rat osteoblasts (45) , disruption of microtubules increased release of PGE 2 . In contrast, our studies with HUVEC show that microtubule disruption using nocodazole or colchicine increased PGE 2 and PGI 2 synthesis but did not increase prostaglandin release. In agreement with our results using HUVEC, treatment of epithelial cells with cytD or nocodazole increased COX-2 protein expression (41) . When HUVEC were treated with nocodazole or colchicine to disrupt microtubules, we observed an apparent increase in the number and thickness of stress fiber bundles. Increased stress fiber formation has been observed previously in fibroblasts in response to microtubule disruption (7) . The lack of prostaglandin release from HUVEC treated with nocodazole or colchicine, however, suggests that some other signal is required for release of the prostaglandins into the extracellular environment.
Disruption of the actin or microtubule cytoskeleton could increase prostaglandin synthesis by increasing COX-2 activity through a mechanism involving posttranslational modification of COX-2 by tyrosine phosphorylation, as previously suggested (32) . However, we found no evidence for increases in tyrosine phosphorylation of COX-2 in response to disruption of either microfilaments or microtubules (Fig. 6) . Alternatively, prostaglandin synthesis could be regulated by the subcellular localization of COX-2. COX-2 is normally localized to the endoplasmic reticulum and nuclear membranes (40) . Although immunolocalization of COX-2 in cells with disrupted microfilaments and microtubules did not reveal gross changes in COX-2 localization compared with vehicle-treated controls (Sawyer, unpublished results), it remains possible that accessibility of COX-2 to free AA may be increased by cytoskeletal disruption.
Another possible mechanism for increased prostaglandin synthesis from HUVEC following disruption of microfilaments or microtubules may involve increased membrane fluidity and PLA 2 activity. Disruption of microfilaments or microtubules increases membrane fluidity in epithelial cells and leukocytes (26, 31, 44) , and increased membrane fluidity activates PLA 2 in fibroblast cells (5) . Because PLA 2 cleaves phospholipids to release AA, the substrate for COX-2 disrupting either microfilaments or microtubules may increase prostaglandin synthesis by activating PLA 2 and increasing pools of AA without requiring new COX-2 synthesis. Although after cytoskeletal disruption we measured a decrease in PLA 2 in cell extracts using an in vitro PLA 2 activity assay, further studies will be required to determine whether changes in membrane fluidity and PLA 2 activity might be involved in increased prostaglandin synthesis in HUVEC with a disrupted cytoskeleton.
Both the actin and microtubule cytoskeletons are clearly involved in the regulation of endothelial barrier function. Treatment of endothelial cells with TNF-␣ or hypoxia disrupts barrier function and induces actin depolymerization (16, 17, 29) , while LPS disrupts barrier function and depolymerizes microfilaments and microtubules (16) . Barrier dysfunction also correlates with increased release of prostaglandins that are vasoprotective, that is, these prostaglandins may function to protect barrier integrity. For example, hypoxia, LPS, and endotoxin, all of which cause endothelial barrier dysfunction, also stimulate release of PGI 2 and induce COX-2 mRNA and protein expression (2, 22, 23, 36) . Addition of exogenous prostaglandins, including PGE 2 and PGI 2 , can actually enhance endothelial barrier function (24, 43) and prevent hypoxia-induced endothelial barrier dysfunction (6) . Furthermore, prostaglandins that prevent hypoxia-, LPS-, and endotoxininduced barrier dysfunction also stabilize microfilaments. We propose that increased PGE 2 and PGI 2 released in response to microfilament disruption may act in a paracrine/autocrine fashion to restore barrier function. Although the precise mechanisms remain to be determined, our results, together with studies demonstrating a vasoprotective role for prostaglandins, suggest an important role for the cytoskeleton in maintaining endothelial barrier function through regulating prostaglandin synthesis and release.
